Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings. We have evaluated the effectiveness of different factor concentrates at reversing modifications of hemostatic mechanisms induced by moderately elevated concentrations of apixaban (200 ng/ml) adde...

The properties of dry collodion membranes previously described allow the prediction that cells of these membranes will concentrate solutes under certain conditions. Three such cases have been studied experimentally. 1. A membrane containing thiosulphate and immersed in a solution of iodine concentrates iodide ion. 2. A membrane containing sodium chromate and immersed in mercury chloride concent...